A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

Publication: 2004- : Chichester, West Sussex, England : Wiley
Original Publication: Oxford, U.K. ; Vista, CA : Update Software,

Anti-Bacterial Agents/*therapeutic use ; Endocarditis, Bacterial/*drug therapy; Anti-Bacterial Agents/adverse effects ; Endocarditis, Bacterial/microbiology ; Endocarditis, Bacterial/mortality ; Female ; Fosfomycin/adverse effects ; Fosfomycin/therapeutic use ; Humans ; Imipenem/adverse effects ; Imipenem/therapeutic use ; Levofloxacin/adverse effects ; Levofloxacin/therapeutic use ; Male ; Penicillins/adverse effects ; Penicillins/therapeutic use ; Randomized Controlled Trials as Topic ; Vancomycin/adverse effects ; Vancomycin/therapeutic use

Background: Infective endocarditis is a microbial infection of the endocardial surface of the heart. Antibiotics are the cornerstone of treatment, but due to the differences in presentation, populations affected, and the wide variety of micro-organisms that can be responsible, their use is not standardised. This is an update of a review previously published in 2016.
Objectives: To assess the existing evidence about the clinical benefits and harms of different antibiotics regimens used to treat people with infective endocarditis.
Search Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase Classic and Embase, LILACS, CINAHL, and the Conference Proceedings Citation Index - Science on 6 January 2020. We also searched three trials registers and handsearched the reference lists of included papers. We applied no language restrictions.
Selection Criteria: We included randomised controlled trials (RCTs) assessing the effects of antibiotic regimens for treating definitive infective endocarditis diagnosed according to modified Duke's criteria. We considered all-cause mortality, cure rates, and adverse events as the primary outcomes. We excluded people with possible infective endocarditis and pregnant women.
Data Collection and Analysis: Two review authors independently performed study selection, 'Risk of bias' assessment, and data extraction in duplicate. We constructed 'Summary of findings' tables and used GRADE methodology to assess the quality of the evidence. We described the included studies narratively.
Main Results: Six small RCTs involving 1143 allocated/632 analysed participants met the inclusion criteria of this first update. The included trials had a high risk of bias. Three trials were sponsored by drug companies. Due to heterogeneity in outcome definitions and different antibiotics used data could not be pooled. The included trials compared miscellaneous antibiotic schedules having uncertain effects for all of the prespecified outcomes in this review. Evidence was either low or very low quality due to high risk of bias and very low number of events and small sample size. The results for all-cause mortality were as follows: one trial compared quinolone (levofloxacin) plus standard treatment (antistaphylococcal penicillin (cloxacillin or dicloxacillin), aminoglycoside (tobramycin or netilmicin), and rifampicin) versus standard treatment alone and reported 8/31 (26%) with levofloxacin plus standard treatment versus 9/39 (23%) with standard treatment alone; risk ratio (RR) 1.12, 95% confidence interval (CI) 0.49 to 2.56. One trial compared fosfomycin plus imipenem 3/4 (75%) versus vancomycin 0/4 (0%) (RR 7.00, 95% CI 0.47 to 103.27), and one trial compared partial oral treatment 7/201 (3.5%) versus conventional intravenous treatment 13/199 (6.53%) (RR 0.53, 95% CI 0.22 to 1.31). The results for rates of cure with or without surgery were as follows: one trial compared daptomycin versus low-dose gentamicin plus an antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or vancomycin and reported 9/28 (32.1%) with daptomycin versus 9/25 (36%) with low-dose gentamicin plus antistaphylococcal penicillin or vancomycin; RR 0.89, 95% CI 0.42 to 1.89. One trial compared glycopeptide (vancomycin or teicoplanin) plus gentamicin with cloxacillin plus gentamicin (13/23 (56%) versus 11/11 (100%); RR 0.59, 95% CI 0.40 to 0.85). One trial compared ceftriaxone plus gentamicin versus ceftriaxone alone (15/34 (44%) versus 21/33 (64%); RR 0.69, 95% CI 0.44 to 1.10), and one trial compared fosfomycin plus imipenem versus vancomycin (1/4 (25%) versus 2/4 (50%); RR 0.50, 95% CI 0.07 to 3.55). The included trials reported adverse events, the need for cardiac surgical interventions, and rates of uncontrolled infection, congestive heart failure, relapse of endocarditis, and septic emboli, and found no conclusive differences between groups (very low-quality evidence). No trials assessed quality of life.
Authors' Conclusions: This first update confirms the findings of the original version of the review. Limited and low to very low-quality evidence suggests that the comparative effects of different antibiotic regimens in terms of cure rates or other relevant clinical outcomes are uncertain. The conclusions of this updated Cochrane Review were based on few RCTs with a high risk of bias. Accordingly, current evidence does not support or reject any regimen of antibiotic therapy for the treatment of infective endocarditis.
(Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)

Update of: Cochrane Database Syst Rev. 2016 Apr 19;4:CD009880. (PMID: 27092951)

Med J Aust. 2013 Mar 18;198(5):270-2. (PMID: 23496404)
Presse Med. 2019 May;48(5):513-521. (PMID: 31056234)
Infez Med. 2016 Sep 1;24(3):190-3. (PMID: 27668898)
Clin Infect Dis. 2018 Jul 2;67(2):303-309. (PMID: 29390132)
Clin Microbiol Infect. 2017 Oct;23(10):736-739. (PMID: 28323194)
Res Synth Methods. 2010 Jul;1(3-4):169-84. (PMID: 26061464)
J Clin Epidemiol. 2011 Apr;64(4):401-6. (PMID: 21208779)
Medicina (B Aires). 2019;79(4):257-264. (PMID: 31487244)
Curr Infect Dis Rep. 2013 Aug;15(4):342-6. (PMID: 23737237)
Curr Top Microbiol Immunol. 2016;397:257-82. (PMID: 27460814)
J Clin Epidemiol. 2011 Apr;64(4):395-400. (PMID: 21194891)
Infect Immun. 2010 Nov;78(11):4936-43. (PMID: 20713628)
Clin Microbiol Infect. 2018 Jun;24(6):673-676. (PMID: 29408610)
Circulation. 2015 Feb 10;131(6):571-81. (PMID: 25527699)
Microbes Infect. 2011 Mar;13(3):216-25. (PMID: 21044892)
Am J Med. 1994 Mar;96(3):211-9. (PMID: 8154508)
Herz. 2001 Sep;26(6):379-90. (PMID: 11683068)
Asian Cardiovasc Thorac Ann. 2018 Sep;26(7):517-523. (PMID: 30185074)
Clin Microbiol Infect. 2017 Dec;23(12):900-906. (PMID: 28487168)
Clin Infect Dis. 2014 Oct 15;59(8):1105-12. (PMID: 25048851)
Ann Intern Med. 1979 May;90(5):789-91. (PMID: 434682)
Catheter Cardiovasc Interv. 2019 Oct 1;94(4):625-635. (PMID: 31471941)
Neuro Endocrinol Lett. 2019 Mar;39(8):544-549. (PMID: 30927759)
Curr Opin Infect Dis. 2006 Dec;19(6):544-50. (PMID: 17075329)
Int J Cardiol. 2015;190:151-6. (PMID: 25918069)
Clin Infect Dis. 2001 Jul 1;33(1):120-5. (PMID: 11389505)
Clin Infect Dis. 2009 Mar 15;48(6):713-21. (PMID: 19207079)
Antimicrob Agents Chemother. 1984 Jan;25(1):16-9. (PMID: 6703681)
Drug Saf. 2010 May 1;33(5):353-69. (PMID: 20397737)
Gen Hosp Psychiatry. 2019 Mar - Apr;57:44-49. (PMID: 30908961)
Expert Opin Drug Saf. 2012 May;11(3):381-99. (PMID: 22220627)
J Antimicrob Chemother. 2008 Nov;62 Suppl 3:iii25-33. (PMID: 18829722)
Cardiovasc Pathol. 2006 Sep-Oct;15(5):256-263. (PMID: 16979032)
Am Heart J. 2013 Feb;165(2):116-22. (PMID: 23351813)
Heart Lung. 2015 Jul-Aug;44(4):317-20. (PMID: 25998992)
J Antimicrob Chemother. 2008 Dec;62(6):1413-21. (PMID: 18782781)
EuroIntervention. 2019 Aug 09;15(6):e500-e507. (PMID: 31113766)
Ann Intern Med. 1981 Apr;94(4 pt 1):505-18. (PMID: 7011141)
Nat Rev Cardiol. 2019 Oct;16(10):623-635. (PMID: 31175343)
JAMA. 2012 Apr 18;307(15):1636-40. (PMID: 22511692)
Am J Emerg Med. 2018 Sep;36(9):1686-1692. (PMID: 30001813)
J Clin Epidemiol. 2011 Dec;64(12):1294-302. (PMID: 21803546)
Expert Opin Pharmacother. 2019 Apr;20(6):751-772. (PMID: 30785333)
Tex Heart Inst J. 2015 Apr 01;42(2):172-4. (PMID: 25873834)
Ann Intern Med. 2004 Nov 16;141(10):781-8. (PMID: 15545678)
Ann Intern Med. 1992 Sep 1;117(5):390-8. (PMID: 1503330)
Rev Soc Bras Med Trop. 2019 Jun 06;52:e2018375. (PMID: 31188916)
Cardiovasc Diagn Ther. 2017 Feb;7(1):27-35. (PMID: 28164010)
Nat Rev Dis Primers. 2016 Sep 01;2:16059. (PMID: 27582414)
Thorac Cardiovasc Surg. 2017 Dec;65(8):634-638. (PMID: 28922673)
Eur Neurol. 2018;80(3-4):171-178. (PMID: 30485851)
BMC Infect Dis. 2019 Jan 31;19(1):102. (PMID: 30704409)
N Engl J Med. 2012 Aug 30;367(9):787-90. (PMID: 22830434)
Am J Med. 1996 Jul;101(1):68-76. (PMID: 8686718)
BMJ Open. 2014 Jun 24;4(6):e004744. (PMID: 24961714)
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1021-1029.e5. (PMID: 28992971)
Presse Med. 2019 May;48(5):549-555. (PMID: 31109767)
PLoS One. 2013 Dec 09;8(12):e82665. (PMID: 24349331)
Scand J Infect Dis. 1996;28(4):399-406. (PMID: 8893406)
Drugs. 2008;68(4):535-65. (PMID: 18318569)
J Nucl Cardiol. 2019 Feb;26(1):309-312. (PMID: 30132186)
Crit Care Med. 2019 Aug;47(8):e685-e692. (PMID: 31149963)
J Antimicrob Chemother. 2015 Aug;70(8):2382-8. (PMID: 25925595)
Clin Infect Dis. 2000 Apr;30(4):633-8. (PMID: 10770721)
FP Essent. 2017 Jun;457:30-38. (PMID: 28671807)
Drugs Aging. 2019 Feb;36(2):115-124. (PMID: 30488173)
J Clin Epidemiol. 2011 Dec;64(12):1311-6. (PMID: 21802902)
Ann Intern Med. 1991 Nov 1;115(9):674-80. (PMID: 1929035)
Anesth Analg. 2018 Feb;126(2):691-698. (PMID: 29346210)
Microbiology (Reading). 2018 Oct;164(10):1254-1265. (PMID: 30091695)
Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):159-68. (PMID: 26585337)
Ann Intern Med. 1996 Dec 15;125(12):969-74. (PMID: 8967707)
J Antimicrob Chemother. 2007 Nov;60(5):921-8. (PMID: 17881630)
J Heart Valve Dis. 2014 Nov;23(6):735-43. (PMID: 25790621)
Indian J Pathol Microbiol. 2007 Oct;50(4):685-97. (PMID: 18306530)
BMJ. 2010 Mar 23;340:c869. (PMID: 20332511)
Stat Med. 2016 Jul 20;35(16):2687-714. (PMID: 26914402)
Eur Heart J. 2019 Oct 14;40(39):3222-3232. (PMID: 31504413)
Clin Microbiol Infect. 2018 Aug;24(8):916-917. (PMID: 29559393)
Clin Microbiol Rev. 2013 Oct;26(4):759-80. (PMID: 24092854)
Pharm Stat. 2007 Jul-Sep;6(3):161-70. (PMID: 17674404)
J Clin Epidemiol. 2011 Dec;64(12):1283-93. (PMID: 21839614)
N Engl J Med. 2019 Jan 31;380(5):415-424. (PMID: 30152252)
PLoS One. 2018 Aug 9;13(8):e0201459. (PMID: 30092074)
Curr Infect Dis Rep. 2006 Jun;8(4):271-9. (PMID: 16822370)
Tex Heart Inst J. 2017 Feb 1;44(1):10-15. (PMID: 28265207)
Nat Rev Cardiol. 2014 Jan;11(1):35-50. (PMID: 24247105)
Curr Infect Dis Rep. 2017 May;19(5):21. (PMID: 28401448)
J Infect Chemother. 2019 Dec;25(12):965-971. (PMID: 31320197)
Infection. 2019 Dec;47(6):879-895. (PMID: 31254171)
Ann Intern Med. 1982 Oct;97(4):496-503. (PMID: 6751182)
Rev Infect Dis. 1991 Jan-Feb;13 Suppl 2:S160-3. (PMID: 2017645)
J Antimicrob Chemother. 2007 Jul;60(1):7-19. (PMID: 17550889)
Infect Dis Clin North Am. 2009 Dec;23(4):1053-75, x. (PMID: 19909897)
BMJ. 2013 Jan 08;346:e7586. (PMID: 23303884)
Presse Med. 2019 May;48(5):532-538. (PMID: 31056233)
Curr Neurol Neurosci Rep. 2019 Mar 30;19(5):23. (PMID: 30927133)
J Nucl Cardiol. 2019 Feb;26(1):303-308. (PMID: 29923105)
Perfusion. 2020 May;35(4):290-296. (PMID: 31480970)
Nat Rev Microbiol. 2010 Sep;8(9):623-33. (PMID: 20676145)
Nat Rev Microbiol. 2016 Aug 11;14(9):563-75. (PMID: 27510863)
J Clin Epidemiol. 2009 Oct;62(10):e1-34. (PMID: 19631507)
Int J Antimicrob Agents. 2011 Feb;37(2):95-101. (PMID: 21130609)
Mayo Clin Proc. 2011 Feb;86(2):156-67. (PMID: 21282489)
Crit Care Clin. 2008 Apr;24(2):421-42, xi. (PMID: 18361954)
Microb Pathog. 2019 Jun;131:259-269. (PMID: 31002964)
Microbiol Spectr. 2019 Mar;7(2):. (PMID: 30927347)
Med Clin North Am. 2010 Jul;94(4):805-20, xii. (PMID: 20609864)
Circulation. 2015 Oct 13;132(15):1435-86. (PMID: 26373316)
Infect Dis Clin North Am. 2009 Dec;23(4):965-82, ix. (PMID: 19909893)
Enferm Infecc Microbiol Clin. 2010 Oct;28(8):498-503. (PMID: 20188444)
Open Forum Infect Dis. 2019 Mar 01;6(4):ofz089. (PMID: 30949535)
J Antimicrob Chemother. 2006 Apr;57(4):639-47. (PMID: 16501057)
J Am Coll Cardiol. 2015 Jan 27;65(3):307-9. (PMID: 25614430)
J Assoc Physicians India. 2018 Jun;66(6):60-65. (PMID: 31331138)
Cardiol Ther. 2019 Dec;8(2):167-177. (PMID: 31535282)
J Intern Med. 2006 Feb;259(2):179-90. (PMID: 16420547)
Clin Microbiol Infect. 2007 Feb;13(2):211-215. (PMID: 17328738)
Eur Heart J. 2015 Nov 21;36(44):3075-3128. (PMID: 26320109)
Cochrane Database Syst Rev. 2016 Apr 19;4:CD009880. (PMID: 27092951)
N Engl J Med. 2006 Aug 17;355(7):653-65. (PMID: 16914701)
Ann Intern Med. 2004 May 18;140(10):795-801. (PMID: 15148066)
Can J Cardiol. 2019 Jun;35(6):721-726. (PMID: 31151707)
Turk Kardiyol Dern Ars. 2020 Mar;48(2):187-226. (PMID: 32147661)
Ann N Y Acad Sci. 2011 Mar;1222:49-54. (PMID: 21434942)
Heart. 2006 Nov;92(11):1694-700. (PMID: 17041124)
J Antimicrob Chemother. 2014 May;69(5):1407-15. (PMID: 24398341)
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv3-iv6. (PMID: 21521705)
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1753-1763. (PMID: 31187307)
Mult Scler. 2017 Apr;23(5):644-646. (PMID: 28273773)
J Clin Epidemiol. 2011 Dec;64(12):1277-82. (PMID: 21802904)
PLoS One. 2017 Apr 13;12(4):e0174519. (PMID: 28407024)
Mod Healthc. 2012 Jan 30;42(5):12-3. (PMID: 22356074)
Korean J Intern Med. 2015 Jul;30(4):434-42. (PMID: 26175567)
Cleve Clin J Med. 2019 Aug;86(8):559-567. (PMID: 31385793)
Pan Afr Med J. 2017 Jan 30;26:40. (PMID: 28451018)
Stroke. 2019 May;50(5):1046-1051. (PMID: 30896327)
Eur J Clin Microbiol Infect Dis. 2016 Aug;35(8):1227-45. (PMID: 27170145)
Antimicrob Agents Chemother. 1995 Feb;39(2):525-8. (PMID: 7726526)
Neth J Med. 2011 Sep;69(9):379-83. (PMID: 21978980)
Infect Dis (Lond). 2016;48(5):373-8. (PMID: 26950685)
Am J Med. 1994 Mar;96(3):200-9. (PMID: 8154507)
Infect Immun. 2010 Oct;78(10):4268-75. (PMID: 20696834)
BMJ. 1999 Sep 11;319(7211):670-4. (PMID: 10480822)
J Clin Med. 2019 Aug 04;8(8):. (PMID: 31382658)
Indian Heart J. 2018 Mar - Apr;70(2):225-232. (PMID: 29716699)
Int J Environ Res Public Health. 2019 Jun 25;16(12):. (PMID: 31242695)
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv7-iv15. (PMID: 21521707)
Front Cell Infect Microbiol. 2017 Jun 30;7:286. (PMID: 28713774)
BMJ. 2008 May 3;336(7651):995-8. (PMID: 18456631)
Cureus. 2019 May 10;11(5):e4635. (PMID: 31312561)
Catheter Cardiovasc Interv. 2018 Feb 1;91(2):277-284. (PMID: 28895275)
J Clin Epidemiol. 2011 Dec;64(12):1303-10. (PMID: 21802903)
J Bacteriol. 2019 Jun 21;201(14):. (PMID: 30962356)
JACC Cardiovasc Interv. 2015 Feb;8(2):334-346. (PMID: 25700757)
J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583)
Internist (Berl). 2019 Oct;60(10):1111-1117. (PMID: 31444523)
QJM. 2019 Dec 1;112(12):900-906. (PMID: 31359051)
Lancet. 2016 Feb 27;387(10021):882-93. (PMID: 26341945)
Mini Rev Med Chem. 2012 Mar;12(3):202-9. (PMID: 22356191)
Clin Infect Dis. 1998 Dec;27(6):1470-4. (PMID: 9868662)
Antimicrob Agents Chemother. 1991 Jan;35(1):79-87. (PMID: 1826594)
J Clin Epidemiol. 2011 Apr;64(4):407-15. (PMID: 21247734)
BMJ. 2011 Jul 22;343:d4002. (PMID: 21784880)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)

0 (Anti-Bacterial Agents)
0 (Penicillins)
2N81MY12TE (Fosfomycin)
6GNT3Y5LMF (Levofloxacin)
6Q205EH1VU (Vancomycin)
71OTZ9ZE0A (Imipenem)

Date Created: 20200515 Date Completed: 20200911 Latest Revision: 20210514

20240829

PMC7527143

10.1002/14651858.CD009880.pub3

32407558